Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk.
about
Advances in the Study of the Antiatherogenic Function and Novel Therapies for HDLNew Era of Lipid-Lowering DrugsDiscovery and refinement of loci associated with lipid levels.Genetic variants in CETP increase risk of intracerebral hemorrhage.CETP inhibitors and cardiovascular disease: Time to think again.Tolerability, pharmacokinetics and pharmacodynamics of TA-8995, a selective cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects.A vaccine targeted at CETP alleviates high fat and high cholesterol diet-induced atherosclerosis and non-alcoholic steatohepatitis in rabbit.Review of the quantitative analysis of cholesteryl ester transfer protein inhibitors.Anacetrapib reduces progression of atherosclerosis, mainly by reducing non-HDL-cholesterol, improves lesion stability and adds to the beneficial effects of atorvastatin.Effects of whole grain, fish and bilberries on serum metabolic profile and lipid transfer protein activities: a randomized trial (Sysdimet).Increased plasma cholesterol esterification by LCAT reduces diet-induced atherosclerosis in SR-BI knockout mice.Apoc2 loss-of-function zebrafish mutant as a genetic model of hyperlipidemia.Alterations in lipid transfers to HDL associated with the presence of coronary artery disease in patients with type 2 diabetes mellitusCETP/LPL/LIPC gene polymorphisms and susceptibility to age-related macular degeneration.New molecular insights into CETP structure and function: a review.Human serum preβ1-high density lipoprotein levels are independently and negatively associated with coronary artery diseases.Future of cholesteryl ester transfer protein (CETP) inhibitors: a pharmacological perspective.Single nucleotide polymorphisms in cholesteryl ester transfer protein gene and recurrent coronary heart disease or mortality in patients with established atherosclerosis.High density lipoprotein: a therapeutic target in type 2 diabetes.Ethanol inhibits activation of NLRP3 and AIM2 inflammasomes in human macrophages--a novel anti-inflammatory action of alcoholDisease-associated marked hyperalphalipoproteinemia.Lymphatic transport of high-density lipoproteins and chylomicrons.Pharmacogenomics of high-density lipoprotein-cholesterol-raising therapies.Genetics of HDL-C: a causal link to atherosclerosis?Demystifying the management of hypertriglyceridaemia.Oral retinoids and plasma lipids.Ongoing challenges for pharmacotherapy for dyslipidemia.Chemical Genetic Approaches for the Investigation of Neutral Lipid Metabolism.Mendelian Randomization Analyses for Selection of Therapeutic Targets for Cardiovascular Disease Prevention: a Note of Circumspection.High-density lipoprotein reduces inflammation from cholesterol crystals by inhibiting inflammasome activation.Plaque imaging to refine indications for emerging lipid-lowering drugs.Hepatic expression of inflammatory genes and microRNAs in pigs with high "cholesteryl ester transfer protein" (CETP) activity.Moringa Leaves Prevent Hepatic Lipid Accumulation and Inflammation in Guinea Pigs by Reducing the Expression of Genes Involved in Lipid Metabolism.A novel swine model for evaluation of dyslipidemia and atherosclerosis induced by human CETP overexpression.CETP Lowers TLR4 Expression Which Attenuates the Inflammatory Response Induced by LPS and Polymicrobial Sepsis.Reduction in PCSK9 levels induced by anacetrapib: an off-target effect?New lipid and lipoprotein targets for the treatment of cardiometabolic diseases.High-density lipoprotein cholesterol targeting for novel drug discovery: where have we gone wrong?High-density lipoprotein metabolism and reverse cholesterol transport: strategies for raising HDL cholesterol.HDL--is it too big to fail?
P2860
Q26801507-DC1032D0-B23C-4D48-867E-7DF313D965D0Q28072298-733B7278-73DD-4EF5-B586-60CB7D76F776Q28661470-92BF2D5D-C551-481C-97E0-2A7A69A501F9Q30275688-1856CC3E-55A6-414F-BF7E-075B131969E5Q34109100-9997456F-5B2C-47F2-BCCA-DB5E503AF220Q34571030-C8739EEC-4A7B-4BA9-9C69-95BDC5AC3B37Q34653513-25BAC866-9F5D-42E8-9226-27B2E540F67AQ34708105-E280E3AA-3CB4-493A-93AE-B0CC532C4DEAQ34858025-8CB461F2-AC3B-4596-B8E4-BE1428C81990Q35108988-88B7059F-FEE0-4EAE-89E5-FD022AA195F2Q35776623-55AFF7C2-10E5-4B8E-9E1F-64EE54EB6292Q35923466-DEFE7144-C8B6-4C65-99E2-E9A98D4C1EA3Q35950004-180718F4-05DD-410D-9001-F766473026D0Q36209833-4AF702C8-EA03-4028-8BD3-A581CDF99DF3Q36520363-6F4C8197-AD80-4857-978D-7F6CF1C48099Q36907281-8180731A-0BAA-4125-B1A3-FFCBCEEB6196Q37038670-6F7E3ED8-6C96-4AB9-804A-8803C0CDEDF1Q37239358-C246BC41-88CB-436A-A6D4-92386D62D256Q37264429-5D8E084A-D975-4C83-9DF0-D2DD1DF1C8ABQ37297453-4E9B3E2F-76D8-4010-9CE5-0A515A7AB380Q37434051-4E0DC10A-4114-4B1B-8C6D-4FE623A51650Q37602219-AB1ECF25-ED63-4B31-B01C-EE4CE8F38F0AQ37695401-3B23DEA0-F269-42D9-AB73-977EC1D24B57Q38099536-DDD0823F-406C-4A9F-9E23-9345394D2F61Q38141575-6B2F58DD-864A-45F6-B02B-F0D27685C1E9Q38149925-ED5719D5-0C15-4D1D-BBA7-5590986EEDBCQ38283386-E1D10E67-9D85-41B7-8603-5D62F0E008DDQ38682493-3E737240-ECD4-4DB9-A06E-D841EFFB067AQ38707328-378895AD-BF11-4FBE-8088-08216A375E73Q38762941-D082A62C-D251-428E-A645-6166DE34D4BCQ39000038-9230884A-0374-436C-993F-03AA0C41568BQ39725525-F656162D-1AD5-4017-83A3-027429C3AC25Q41181133-3D0DFB1D-B8ED-4EEF-A16D-BB3FE21508F2Q41278125-C9620104-CFFD-4AF6-A45F-AFA9995BDD88Q42103732-7E0F5A28-0E91-403C-AA6B-B75A7E532BF7Q43204658-71926337-FB6C-4A0C-BBEE-380E157DEAC8Q43237185-47B10D62-11B1-456A-9F36-FB55A26CF43EQ43498643-FF825FC6-3B9D-4D55-89D0-CF46A129B199Q45870343-9D2E91DB-EEC3-4D7D-A246-076F7281930BQ46866176-4E128AB7-BE1B-40D7-853F-E0A9DA36730B
P2860
Cholesteryl ester transfer protein inhibition as a strategy to reduce cardiovascular risk.
description
2012 nî lūn-bûn
@nan
2012 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Cholesteryl ester transfer pro ...... to reduce cardiovascular risk.
@ast
Cholesteryl ester transfer pro ...... to reduce cardiovascular risk.
@en
Cholesteryl ester transfer pro ...... to reduce cardiovascular risk.
@nl
type
label
Cholesteryl ester transfer pro ...... to reduce cardiovascular risk.
@ast
Cholesteryl ester transfer pro ...... to reduce cardiovascular risk.
@en
Cholesteryl ester transfer pro ...... to reduce cardiovascular risk.
@nl
prefLabel
Cholesteryl ester transfer pro ...... to reduce cardiovascular risk.
@ast
Cholesteryl ester transfer pro ...... to reduce cardiovascular risk.
@en
Cholesteryl ester transfer pro ...... to reduce cardiovascular risk.
@nl
P2860
P356
P1476
Cholesteryl ester transfer pro ...... to reduce cardiovascular risk.
@en
P2093
Kerry-Anne Rye
Philip J Barter
P2860
P304
P356
10.1194/JLR.R024075
P577
2012-05-22T00:00:00Z